Cargando…
Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry
BACKGROUND: Biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARD) are widely used for treatment of rheumatoid arthritis (RA), enabling patients to better achieve remission. OBJECTIVE: The objective of the study was to investigate and compare remission rates in RA patients...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109493/ https://www.ncbi.nlm.nih.gov/pubmed/35586514 http://dx.doi.org/10.1177/1759720X221096363 |
_version_ | 1784708911516876800 |
---|---|
author | Koh, Jung Hee Lee, Yusun Kim, Hyoun-Ah Kim, Jinhyun Shin, Kichul |
author_facet | Koh, Jung Hee Lee, Yusun Kim, Hyoun-Ah Kim, Jinhyun Shin, Kichul |
author_sort | Koh, Jung Hee |
collection | PubMed |
description | BACKGROUND: Biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARD) are widely used for treatment of rheumatoid arthritis (RA), enabling patients to better achieve remission. OBJECTIVE: The objective of the study was to investigate and compare remission rates in RA patients treated with different b/tsDMARDs during the period 2013–2019. DESIGN: A longitudinal observational analysis was performed on data from a nationwide RA registry. METHODS: Remission rates in the KOBIO-RA registry were defined by a disease activity score in 28 joints (DAS28), clinical disease activity index (CDAI), simplified disease activity index (SDAI), and Boolean-based assessment. After initiating treatment with b/tsDMARDs, yearly remission rates in response to b/tsDMARDs, either all or as subgroups (tumor necrosis factor-α inhibitors, tocilizumab, abatacept, and Janus kinase inhibitors), were investigated for 5 years. Sustained remission was defined as remission maintained for two consecutive years. RESULTS: Patients (N = 1805) who completed at least one follow-up visit were analyzed (mean age = 55 years; 83.2% female). At month 12, 56.0% of patients achieved remission based on DAS28-C-reactive protein (CRP), 36.2% on DAS28-erythrocyte sedimentation rate (ESR), 10.4% on CDAI, 12.7% on SDAI, and 12.9% on Boolean criteria. Sustained remission rates were 62%, 40%, 13%, 11%, and 8% for the DAS28-CRP, DAS28-ESR, Boolean, SDAI, and CDAI remission criteria, respectively. Remission rates using the DAS28 definition varied most among the b/tsDMARD subgroups. CONCLUSION: Assessment of sustained remission using the CDAI, SDAI, or Boolean criteria is more stringent, yet congruous with the DAS28-based criteria in RA patients treated with b/tsDMARDs. |
format | Online Article Text |
id | pubmed-9109493 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-91094932022-05-17 Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry Koh, Jung Hee Lee, Yusun Kim, Hyoun-Ah Kim, Jinhyun Shin, Kichul Ther Adv Musculoskelet Dis Original Research BACKGROUND: Biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARD) are widely used for treatment of rheumatoid arthritis (RA), enabling patients to better achieve remission. OBJECTIVE: The objective of the study was to investigate and compare remission rates in RA patients treated with different b/tsDMARDs during the period 2013–2019. DESIGN: A longitudinal observational analysis was performed on data from a nationwide RA registry. METHODS: Remission rates in the KOBIO-RA registry were defined by a disease activity score in 28 joints (DAS28), clinical disease activity index (CDAI), simplified disease activity index (SDAI), and Boolean-based assessment. After initiating treatment with b/tsDMARDs, yearly remission rates in response to b/tsDMARDs, either all or as subgroups (tumor necrosis factor-α inhibitors, tocilizumab, abatacept, and Janus kinase inhibitors), were investigated for 5 years. Sustained remission was defined as remission maintained for two consecutive years. RESULTS: Patients (N = 1805) who completed at least one follow-up visit were analyzed (mean age = 55 years; 83.2% female). At month 12, 56.0% of patients achieved remission based on DAS28-C-reactive protein (CRP), 36.2% on DAS28-erythrocyte sedimentation rate (ESR), 10.4% on CDAI, 12.7% on SDAI, and 12.9% on Boolean criteria. Sustained remission rates were 62%, 40%, 13%, 11%, and 8% for the DAS28-CRP, DAS28-ESR, Boolean, SDAI, and CDAI remission criteria, respectively. Remission rates using the DAS28 definition varied most among the b/tsDMARD subgroups. CONCLUSION: Assessment of sustained remission using the CDAI, SDAI, or Boolean criteria is more stringent, yet congruous with the DAS28-based criteria in RA patients treated with b/tsDMARDs. SAGE Publications 2022-05-13 /pmc/articles/PMC9109493/ /pubmed/35586514 http://dx.doi.org/10.1177/1759720X221096363 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Koh, Jung Hee Lee, Yusun Kim, Hyoun-Ah Kim, Jinhyun Shin, Kichul Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry |
title | Comparison of remission criteria in patients with rheumatoid
arthritis treated with biologic or targeted synthetic disease-modifying
anti-rheumatic drugs: results from a nationwide registry |
title_full | Comparison of remission criteria in patients with rheumatoid
arthritis treated with biologic or targeted synthetic disease-modifying
anti-rheumatic drugs: results from a nationwide registry |
title_fullStr | Comparison of remission criteria in patients with rheumatoid
arthritis treated with biologic or targeted synthetic disease-modifying
anti-rheumatic drugs: results from a nationwide registry |
title_full_unstemmed | Comparison of remission criteria in patients with rheumatoid
arthritis treated with biologic or targeted synthetic disease-modifying
anti-rheumatic drugs: results from a nationwide registry |
title_short | Comparison of remission criteria in patients with rheumatoid
arthritis treated with biologic or targeted synthetic disease-modifying
anti-rheumatic drugs: results from a nationwide registry |
title_sort | comparison of remission criteria in patients with rheumatoid
arthritis treated with biologic or targeted synthetic disease-modifying
anti-rheumatic drugs: results from a nationwide registry |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109493/ https://www.ncbi.nlm.nih.gov/pubmed/35586514 http://dx.doi.org/10.1177/1759720X221096363 |
work_keys_str_mv | AT kohjunghee comparisonofremissioncriteriainpatientswithrheumatoidarthritistreatedwithbiologicortargetedsyntheticdiseasemodifyingantirheumaticdrugsresultsfromanationwideregistry AT leeyusun comparisonofremissioncriteriainpatientswithrheumatoidarthritistreatedwithbiologicortargetedsyntheticdiseasemodifyingantirheumaticdrugsresultsfromanationwideregistry AT kimhyounah comparisonofremissioncriteriainpatientswithrheumatoidarthritistreatedwithbiologicortargetedsyntheticdiseasemodifyingantirheumaticdrugsresultsfromanationwideregistry AT kimjinhyun comparisonofremissioncriteriainpatientswithrheumatoidarthritistreatedwithbiologicortargetedsyntheticdiseasemodifyingantirheumaticdrugsresultsfromanationwideregistry AT shinkichul comparisonofremissioncriteriainpatientswithrheumatoidarthritistreatedwithbiologicortargetedsyntheticdiseasemodifyingantirheumaticdrugsresultsfromanationwideregistry |